{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.2","upperLimit":"14.2","value":"5.6"},{"groupId":"OG001","lowerLimit":"1.5","upperLimit":"20.1","value":"14.6"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG002","lowerLimit":"4.3","upperLimit":"NA","value":"NA"},{"groupId":"OG003","lowerLimit":"1.5","upperLimit":"7.0","value":"5.5"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG004","lowerLimit":"2.6","upperLimit":"NA","value":"NA"},{"groupId":"OG005","lowerLimit":"3.6","upperLimit":"24.4","value":"5.4"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG006","lowerLimit":"0.6","upperLimit":"NA","value":"5.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"6"}],"units":"Participants"}],"description":"OS was defined as the time from the first dose of the study medication until death due to any cause. Only descriptive analysis performed.","dispersionType":"90% Confidence Interval","groups":[{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG000","title":"Cohort 1: Rhabdomyosarcoma (RMS)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG001","title":"Cohort 2: Non-rhabdomyosarcomatous Soft Tissue Sarcoma (NRSTS)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG002","title":"Cohort 3: Ewing Sarcoma/pPNET (Ewing)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG003","title":"Cohort 4 (Osteosarcoma)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG004","title":"Cohort 5: Measurable Neuroblastoma (mNeuroblastoma)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG005","title":"Cohort 6: Evaluable Neuroblastoma (eNeuroblastma)"},{"description":"Subjects were treated with pazopanib GW786034 tablets at a dose of 450 mg/m\\^2/dose or as a powder in suspension at a dose of 225 mg/m\\^2/dose. The maximum daily dose administered was to be 800 mg for the tablet and 400 mg for suspension. If 225 mg/m\\^2/dose was not tolerated (\\>=2 DLTs in 6 evaluable subjects), the dose for subjects who required suspension was reduced to 160 mg/m\\^2/dose. A cycle was defined as 28 days with no rest periods between cycles.","id":"OG006","title":"Cohort 7 (Hepatoblastoma)"}],"paramType":"MEDIAN","populationDescription":"mITT Set","reportingStatus":"POSTED","timeFrame":"From date of first dose of study treatment up to 61 months","title":"Overall Survival (OS) by Cohort","type":"SECONDARY","unitOfMeasure":"Months"}